ArticleCancer medicine2026
Cardiovascular Mortality Risk After Cancer Diagnosis by County-Level Characteristics in the United States 2000-2021.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvances in cancer therapy have improved survival, but cardiovascular disease (CVD) is now the leading non-cancer cause of death among survivors. Specialized cardio-oncology care mitigates risk, yet access remains limited outside of urban academic centers.
methodsWe conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) 17 Registries (2000-2021), including 6,467,098 individuals with first primary malignancies. Outcomes were CVD-specific mortality, estimated using standardized mortality ratios (SMRs) and excess absolute risks (EARs). Exposures were county-level urban/rural status, persistent poverty status, and racial composition. Cancer-specific analyses were additionally performed for major cancer sites to assess heterogeneity in county-level disparities.
resultsDuring follow-up, 394,540 CVD deaths occurred (SMR = 1.11; 95% CI = 1.11, 1.11). Survivors in rural counties (SMR = 1.27), counties with persistent poverty (SMR = 1.35), and those with the highest quartile of Black residents (SMR = 1.15) had significantly higher CVD mortality compared with the general population. The highest risk was observed in rural counties with persistent poverty (SMR = 1.53). Across county groups, CVD mortality peaked within the first year after diagnosis and remained elevated for over a decade in disadvantaged communities. Substantial heterogeneity was found across cancer types in county-level disparities in CVD mortality, with the largest EAR differences observed among survivors of lung and bronchus cancer, followed by corpus uteri, prostate, and urinary bladder cancers.
conclusionsCancer survivors experience substantial and sustained excess CVD mortality, with the greatest disparities in rural and persistently impoverished counties. These findings highlight the need to integrate cardiovascular surveillance into survivorship care and expand access to cardio-oncology services in socially vulnerable communities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.